|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TRIM65 |
Gene summary for TRIM65 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TRIM65 | Gene ID | 201292 |
| Gene name | tripartite motif containing 65 | |
| Gene Alias | 4732463G12Rik | |
| Cytomap | 17q25.1 | |
| Gene Type | protein-coding | GO ID | GO:0006914 | UniProtAcc | Q6PJ69 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 201292 | TRIM65 | HCC1_Meng | Human | Liver | HCC | 2.75e-31 | 3.50e-02 | 0.0246 |
| 201292 | TRIM65 | HCC1 | Human | Liver | HCC | 5.25e-09 | 1.34e+00 | 0.5336 |
| 201292 | TRIM65 | HCC2 | Human | Liver | HCC | 2.75e-14 | 1.44e+00 | 0.5341 |
| 201292 | TRIM65 | HCC5 | Human | Liver | HCC | 3.14e-08 | 1.42e+00 | 0.4932 |
| 201292 | TRIM65 | S014 | Human | Liver | HCC | 9.14e-10 | 4.55e-01 | 0.2254 |
| 201292 | TRIM65 | S015 | Human | Liver | HCC | 6.90e-09 | 4.06e-01 | 0.2375 |
| 201292 | TRIM65 | S016 | Human | Liver | HCC | 1.94e-03 | 3.12e-01 | 0.2243 |
| 201292 | TRIM65 | S027 | Human | Liver | HCC | 5.33e-04 | 3.22e-01 | 0.2446 |
| 201292 | TRIM65 | S028 | Human | Liver | HCC | 1.47e-12 | 3.79e-01 | 0.2503 |
| 201292 | TRIM65 | S029 | Human | Liver | HCC | 2.32e-04 | 2.48e-01 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000989622 | Liver | HCC | positive regulation of catabolic process | 335/7958 | 492/18723 | 3.83e-31 | 1.87e-28 | 335 |
| GO:003133122 | Liver | HCC | positive regulation of cellular catabolic process | 295/7958 | 427/18723 | 3.20e-29 | 1.45e-26 | 295 |
| GO:001050621 | Liver | HCC | regulation of autophagy | 210/7958 | 317/18723 | 7.59e-18 | 8.45e-16 | 210 |
| GO:00105082 | Liver | HCC | positive regulation of autophagy | 81/7958 | 124/18723 | 2.34e-07 | 4.17e-06 | 81 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TRIM65 | SNV | Missense_Mutation | c.466N>A | p.Glu156Lys | p.E156K | Q6PJ69 | protein_coding | tolerated(0.34) | benign(0.243) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response | |
| TRIM65 | SNV | Missense_Mutation | rs765026510 | c.641N>A | p.Arg214Gln | p.R214Q | Q6PJ69 | protein_coding | tolerated(0.71) | benign(0.003) | TCGA-AC-A2B8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | chemo | PD |
| TRIM65 | SNV | Missense_Mutation | c.475N>G | p.Leu159Val | p.L159V | Q6PJ69 | protein_coding | deleterious(0.01) | benign(0.132) | TCGA-AN-A0FL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| TRIM65 | SNV | Missense_Mutation | rs747647313 | c.518N>A | p.Ala173Asp | p.A173D | Q6PJ69 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-C8-A1HK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TRIM65 | SNV | Missense_Mutation | rs199545843 | c.607G>A | p.Glu203Lys | p.E203K | Q6PJ69 | protein_coding | tolerated(0.1) | benign(0.003) | TCGA-EK-A2R8-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| TRIM65 | SNV | Missense_Mutation | c.1105N>C | p.Glu369Gln | p.E369Q | Q6PJ69 | protein_coding | tolerated(0.16) | benign(0.005) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| TRIM65 | SNV | Missense_Mutation | rs767807385 | c.1024N>T | p.Arg342Cys | p.R342C | Q6PJ69 | protein_coding | tolerated(0.09) | benign(0.003) | TCGA-ZJ-AAX4-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
| TRIM65 | SNV | Missense_Mutation | rs765174948 | c.487N>T | p.Arg163Cys | p.R163C | Q6PJ69 | protein_coding | deleterious(0) | benign(0.326) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TRIM65 | SNV | Missense_Mutation | rs200296747 | c.845G>A | p.Arg282Gln | p.R282Q | Q6PJ69 | protein_coding | tolerated(0.98) | benign(0.001) | TCGA-AA-3561-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| TRIM65 | SNV | Missense_Mutation | rs773403074 | c.1040N>T | p.Ser347Leu | p.S347L | Q6PJ69 | protein_coding | deleterious(0) | probably_damaging(0.909) | TCGA-AA-3660-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |